Catecholamines regulate white adipose tissue function and development by acting through β-and α2-adrenergic receptors (ARs). Human adipocytes express mainly α2A-but few or no β3-ARs while the reverse is true for rodent adipocytes. Our aim was to generate a mouse model with a human-like α2/β-adrenergic balance in adipose tissue by creating transgenic mice harbouring the human α2A-AR gene under the control of its own regulatory elements in a combined mouse β3-AR−/− and human β3-AR+/+ background.
Introduction
Obesity is characterized by an excessive development of fat mass which is a consequence of increased fat cell size and/or fat cell number. Several hormones and neurotransmitters regulate adipose tissue development and metabolism. Among them, catecholamines play a major role by acting through 2-and -adrenergic receptors (ARs). They control metabolic effects such as lipolysis through regulation of adenylylcyclase activity and cAMP levels under the balanced control of positive 1-, 2-and 3-AR-dependent stimulation and 2-AR-mediated inhibition (Lafontan & Berlan 1993) . In humans, differences exist in catecholamine-induced lipolysis between fat pads from various anatomical locations. Such differences are related to variations in 2-AR number. Indeed, epinephrine stimulates lipolysis in internal fat depots (omental, pericolonic) whereas it inhibits lipolysis in s.c. fat pads (femoral) where 2-ARs largely outnumber -ARs (Mauriège et al. 1987 , Castan et al. 1993 . Moreover, it has recently been shown, using in situ microdialysis, that the physiological activation of 2-ARs represents an important inhibitory factor for epinephrine-induced lipid mobilization during exercise (Stich et al. 1999) . This impairment of lipolysis is enhanced in obese subjects (Stich et al. 2000) .
Striking species-specific differences exist in fat cell 2-AR expression. The highest level of 2-ARs is observed in primate and human fat cells in which 2-ARs largely predominate over -ARs (Castan et al. 1993 , Lafontan & Berlan 1995 . Moreover, human white adipocytes express few (or no) 3-ARs (Tavernier et al. 1996) . Conversely, most of the laboratory animal models including mice and rats exhibit a very low number of adipocyte 2-ARs . In rodent adipocytes, lipolysis is mainly due to 3-AR activation (Lafontan 1994) . Thus, human and rodent white adipocytes exhibit major differences with respect to the balance between 2-and 3-ARs and catecholamine-dependent regulation of lipolysis.
Since no suitable animal model was available to study the involvement of 2/ -AR balance in white adipose tissue (WAT) in vivo, transgenic approaches were used in mice. Recently, 3-AR gene disruption and human 2A-AR expression in adipose tissues have been described in the Tg(ADRA2A)
Lowl mouse (Valet et al. 2000) . When fed a high-fat diet (HFD), these mice had increased fat mass and body weight. Adipocyte-specific expression of human 2A-ARs in these mice was driven by the aP2 promoter which controls the expression of the associated gene during the early stages of adipocyte differentiation. However, fusing the human 2A-AR gene with the aP2 promoter prevents any endogenous regulation of the 2C10 gene (encoding the 2A-AR). In mammals, regulation of 2-AR gene expression has been related to processes linked to the control of WAT development (Lafontan & Berlan 1995) . Thus, another transgenic approach aiming at the utilization of the regulatory elements of the 2C10 gene and expected to preserve endogenous regulation of 2A-AR appeared complementary. Ito et al. (1998) described a human 3-AR transgene containing the regulatory and coding sequences necessary for a 'human-like' pattern of expression. A genomic P1 clone containing 77 kb of human genomic DNA bearing regulatory elements of the promoter regions and the coding sequences of the human 3-AR were injected into mouse embryo disrupted for the murine 3-AR gene. In this case, 3-AR expression paralleled that commonly described in humans, e.g. expression in brown but not white adipocytes. A similar strategy was applied in the present study for the regulatory elements of the promoter regions and coding sequences of the human 2C10 gene. A 31 kb fragment of human DNA framing the coding sequence of the human 2C10 gene (11 kb upstream and 18 kb downstream) was obtained, characterized and introduced transgenically into (m 3 / , h 3+/+) mice previously described by Ito et al. (1998) . The expression of 2A-AR should then be driven by the regulatory sequences of the human 2C10 gene. A human-like distribution profile of ARs was expected. Therefore, we investigated the expression of human 2A-AR in WAT as well as its regulation regarding fat pad location in transgenic mice. The physiological consequences of an HFD were also studied.
Materials and methods

Transgenic mice
All genetically modified animals were created and maintained on an FVB/n inbred background and were genetically identical except for the specified genetic alterations m 3-AR / , h 2-AR+/ , h 3-AR+/+. Targeted disruption of mouse 3-AR (m 3 / ) generated by homologous recombination (Adrb3 tm1 Low1 ) was described by Susulic et al. (1995) and the introduction of the human 3-AR genomic transgene was reported by Ito et al. (1998) . Finally, the human 2A-AR transgene was constructed accordingly. Briefly, human 2-AR P1 bacteriophage genomic clones were isolated and screened by using specific primers: sense primer 5 -CCTCCAGGGCCCCGCAGACC-3 and antisense primer 5 -AGGGGAACCAGCACACCAC GAACA-3 . The clones were then mapped. A selected P1 clone (DMPC-HFF#1, 69 g6) corresponding to 11 kb upstream of and 18 kb downstream from the 2A-AR-coding region was injected into zygotes of (m 3 / , h 3+/+) mice. Human 2-AR genomic transgene is represented in Fig. 1 . The transgenic mice called Adrb3 tm1 Low1 -Tg (ADRB3-ADRA2A) Lowl mice according to the Jackson guidelines were identified by Southern blotting following PstI digestion of isolated genomic DNA or by PCR with selective primers. After digestion of genomic DNA by PstI enzyme and separation on an agarose gel, three bands of 9, 2.5 and 1 kb on Southern blot reveal the presence of human 2A-AR and 3-AR. These mice will be called transgenic or (m 3 / , h 3+/+, h 2A+/ ) mice in the text. In mice which do not express human 2-AR but human 3-AR, two bands (9 kb and 1 kb) were present. These mice will be called control or (m 3 / , h 3+/+) mice in the text. Transgenic mouse lines were established by breeding transgenic founder mice with their non-transgenic littermates. Nine transgenic founders were generated and three of these were bred to establish lines P1, P3 and P6. Mice from lines P3 and P6 were maintained and analysed. All the results presented in this study were found in both P3 and P6 lines. At all times, the human 3-AR and 2A-AR transgenes were maintained on the murine 3-AR gene knockout background. Transgenic mice could not be distinguished from wild type or control mice by appearance, body weight, fertility or viability.
Diets
After weaning (3 weeks old), mice (male and female) were assigned to a low-fat diet (LFD) or an HFD (UAR, Lyon, France) for 18 weeks. Calorie composition was 20% protein, 70% carbohydrate and 10% fat for the LFD, and 20% protein, 35% carbohydrate and 45% fat for the HFD. The main source of fat in the HFD was lard (20 g/100 g of food). Mice were housed conventionally in an animal room with constant temperature (20-22 C), humidity (50-60%) and with a 12 h light/12 h darkness cycle. Body weight was determined weekly. All mice had free access to food and water throughout the experiment.
Human adipose tissue
Human adipose tissue was collected according to the guidelines of the Ethical Committee of Rangueil Hospital, Toulouse. It was obtained from healthy non-obese women (46 10 years old, body mass index 24·2 1·5, n=5) undergoing abdominal dermolipectomy for plastic surgery. None of them had any identified metabolic disorder or was taking drugs modifying adipose tissue metabolism or catecholamine levels.
Northern blot analyses
Total RNA was extracted from mouse brain, liver, kidney, brown adipose tissue (BAT), WAT (perigonadal and s.c. fat deposits pooled) and human s.c. WAT using RNA STAT (Ams Biotechnology Ltd, Oxon, UK). Fifty microgram aliquots of total RNA were separated by electrophoresis in 1% denaturing MOPS-formaldehydeagarose gels, transferred to nylon membranes and hybridized to a [ 32 P]dCTP-labelled specific probe derived from the 2A-AR gene. However, the probe cannot distinguish between the human 2A subtype and the corresponding rodent subtype formerly called 2D. Ethidium bromide staining of the gel was used to verify the uniformity of loading.
Real-time RT-PCR
Total RNA was extracted using RNA Easy mini (Quiagen) from isolated perigonadal adipocytes of control (m 3 / , h 3+/+) and transgenic (m 3 / , h 3+/+, h 2A+/ ) mice fed an HFD. cDNA was synthesized from 2 µg total RNA using random hexamers and murine Moloney leukaemia virus reverse transcriptase (Life Technologies, Inc.). Real time quantitative RT-PCR analyses were performed as previously described in an ABI PRISM 7700 Sequence Detection System Instrument (Taqman; Applied Biosystems, Foster City, CA, USA) (Le Lay et al. 2001) . GAPDH expression of a control cDNA was used as an interplate calibrator, and the variability in the initial quantities of cDNA was normalized by using ribosomal 18S RNA amplifications. Results were obtained from three or four independent RNA samples from individual animals, each tested in triplicate. 
Radioligand binding studies
The 2-ARs were identified with the selective antagonist radioligand [ 3 H]RX821002 on membranes prepared from isolated white adipocytes and from brain homogenates as previously described (Castan et al. 1993) . The 1-and 2-ARs in fat cell membranes were determined by using the antagonist [
3 H]CGP12177 radioligand as previously described . Specific binding was defined as the difference between total and non-specific binding determined in the presence of 10 5 M phentolamine for the 2-AR and 10 5 M propranolol for the -AR. The maximum number of adrenergic binding sites (B max ) and equilibrium dissociation constants (K d ) were calculated using Scatchard analysis of saturation binding data. Competition studies of [ 3 H]RX821002 binding were performed either on brain membranes from control (m 3 / , h 3+/+) and transgenic (m 3 / , h 3+/+, h 2A+/ ) mice or on adipocyte membranes from human and transgenic mice (a pool of perigonadal and s.c. adipocytes) using 0·01 nM to 10 µM yohimbine and 2 nM of radioligand. Protein content was determined using the Lowry protein assay kit (Bio-Rad, Richmond, CA, USA).
Lipolysis
Perigonadal and s.c. (inguinal) adipose tissues from female mice fed a standard diet or 18 weeks of HFD were quickly dissected. Adipocytes were isolated using collagenase digestion as described previously . They were incubated in the presence of different agents at 37 C and shaken gently for 90 min. Adenosine deaminase (ADA) was used to promote an increment of basal lipolysis in order to measure the antilipolytic effect of the selective 2 agonist, UK14304. The glycerol produced by the cells was used as an index of lipolysis. Total lipids were evaluated gravimetrically after extraction by the method of Dole and Meinertz .
Adipocyte size
Perigonadal adipocytes were isolated as described above. Fifty microlitres of adipocyte suspension were observed under a microscope connected to a camera and then analysed with Visiolab software (Biocom, Les Ulis, France). Two pictures from each preparation were taken and the surface as well as the diameter of each adipocyte (between 30 and 80 adipocytes per photo) was measured.
DNA content of WAT
One hundred milligrams of each adipose tissue sample were minced and digested overnight by proteinase K (NaCl 100 mM, Tris 20 mM, EDTA 10 mM, SDS 1%, proteinase K 100 µg/ml). After salt precipitation, genomic DNA was isolated by ethanol precipitation and DNA content was calculated by spectrophotometry (Ultrospec 3000; Pharmacia Biotech). Linearity and reproducibility of this method was controlled using increasing amounts of adipose tissue.
Serum analyses
At the term of the experiment (21-week-old animals), blood was collected and glucose was immediately measured with a glucose meter (Glucometer 4; Bayer Diagnostics, Puteaux, France). Serum was then taken and immediately frozen. Insulin concentrations were determined with an RIA kit (Diagnostics Pasteur, Paris, France) and non-esterified fatty acids (NEFAs) were measured using a colorimetric enzymatic kit (NEFA C; Wako Pure Chemical Industries, Neuss, Germany).
Glucose tolerance tests
After 6 h fasting, mice fed an HFD for 18 weeks received an i.p. injection of glucose (1 mg/g body weight). Tail vein blood samples were collected before injection and at 10, 20, 30, 60, 120 and 180 min post-injection.
Blood pressure of conscious mice
Blood pressure was measured in control and transgenic mice (male and female) fed an HFD or LFD for 18 weeks. The mice were placed in a semicylindrical container warmed to 30 C and measurements were made indirectly using an inflatable tail-cuff. Prior to the actual blood pressure measurements, the mice were acclimated daily for 1 week to the container. Systolic blood pressure was recorded (15 determinations in a row at three different times) by using a PowerLab/s system connected to CHART software (AD Instruments, Milford, MA, USA).
Statistical analysis
All results are expressed as means S.E.M. Comparisons between groups were made by paired or unpaired Student's t-tests.
Results
Tissue distribution of human 2A-AR mRNA levels in transgenic mice
The presence of human 2A-AR mRNA was first analysed by Northern Blot analysis in different tissues of (m 3 / , h 3+/+) control and (m 3 / , h 3+/+, h 2A+/ ) transgenic mice (Fig. 2) . Human s.c. adipocytes expressing 2A-AR were used as a positive control. In control mice, 2A-AR mRNA was only detected in the brain as expected. In transgenic mice, the human 2A-AR is mainly expressed in WAT and to a much lower extend in BAT. In brain, 2A-AR mRNA was also expressed. The transgene was not detected in kidney or in tissues known to lack 2A-AR in humans like liver. Thus, human 2A-AR expression was extended to WAT in transgenic mice suggesting that the human 2A-AR promoter contains the cis-elements that induce adiposespecific expression of the 2A-AR gene.
Characterization of human 2A-AR in transgenic mice
In order to quantify 2-AR sites, saturation binding experiments were performed with [ 3 H]RX821002, a selective 2-AR antagonist. The results are reported in Table 1 . In tissues known to express endogenous 2-ARs such as brain or kidney, the number of 2-ARs was similar in control and transgenic mice. However, in kidney, the K d value was higher than in other tissues, indicating that the majority of 2-AR belong to another subtype, probably the B subtype as previously described (Uhlen & Wikberg 1991) . In adipose tissues, 2A-AR sites were only expressed in white and not in brown adipocyte membranes of transgenic mice. Nevertheless, the number of 2A-AR binding sites detected in the white fat cells in transgenic mice was much lower than that commonly observed in Figure 2 Northern blot analysis of α2A-AR mRNA in various tissues. Fifty micrograms of total RNA from kidney, liver, brain, brown (BAT) and white (WAT) adipose tissue of control (mβ3−/−, hβ3+/+) and transgenic (mβ3−/−, hβ3+/+, hα2A+/−) female mice (8 weeks old) as well as 50 µg of total RNA from human s.c. WAT were obtained. They were subjected to Northern blot analysis. Corresponding 28S and 18S ribosomal RNA from ethidium bromide-stained gels are shown.
human adipocytes (Castan et al. 1995) . As expected, in the liver, expression of 2A-AR sites was not detected, in agreement with the absence of 2A-AR mRNA.
In order to verify whether the 2-AR receptor identified with [ 3 H]RX821002 was of human or murine origin, competition studies of [ 3 H]RX821002 binding were performed in the presence of yohimbine (an 2-AR antagonist) in brain and adipocyte membranes. Indeed, it has been shown that yohimbine has a very low affinity for the rodent compared with human 2A-AR (Link et al. 1992 , Uhlen et al. 1998 . In brain from transgenic as well as control mice, yohimbine inhibited the binding of [ 3 H]RX821002 in a concentration-dependent manner, displaying a similar population of low-affinity receptors (K i = 135 47 nM and 89 38 nM respectively, n=5). By contrast, the K i values in adipocyte membranes from transgenic mice (K i =6·7 1·3 nM, n=5) revealed a population of high-affinity receptors which was similar to that obtained in humans (K i =4·6 1·1 nM, n=5) (Fig. 3) . This result indicates that the 2A-AR expressed in the brain of transgenic mice is essentially of the murine type whereas it is of the human type in WAT. Thus, the human 2A-AR protein is mainly expressed in WAT and not in brain of transgenic mice.
Regulation of 2A-AR expression according to the location of the fat deposit
The distribution of the 2A-AR differs according to fat location in humans. Since the expression of the 2A-AR was under the control of human gene regulatory elements in transgenic mice, the level of expression of 2A-ARs was investigated in two different fat deposits. Strikingly, 2A-ARs were more numerous in male and female s.c. than in perigonadal adipocytes (Fig. 4A ) from transgenic mice. Expression of 1-and 2-ARs was also determined in isolated adipocytes from control and transgenic mice (female) by using [ 3 H]CGP12177, a 1-, 2-AR antagonist. The maximum number of sites for both 1-and 2-ARs was similar between control and transgenic mice without differences according to fat pad location (18 1 
Regulation of lipolysis in transgenic mice expressing human 2A-AR
It was expected that a higher expression of 2A-AR in s.c. adipocytes should be related to a lower lipolytic response to catecholamines. In order to assess the efficiency of the 2-adrenergic responsiveness in the different fat pads, isolated adipocytes from transgenic female mice were stimulated with different concentrations of the endogenous amine epinephrine alone or in the presence of 10 5 M RX821002, a selective 2 antagonist. Isoproterenol at 10 5 M was also tested as a positive control for the maximal lipolysis induced by 1-and 2-ARs stimulation. Epinephrine promoted glycerol release with a significant effect at 10 6 M and 10 5 M in both perigonadal and s.c. adipocytes. When RX821002 was added to the incubation medium, a significant increment in the lipolytic effect of 10 5 M epinephrine was obtained. It was significantly stronger in s.c. than in perigonadal adipocytes ( Fig. 4B and C) . The maximum effect at 10 6 M epinephrine plus 10 5 M RX821002 was similar to that of isoproterenol in both fat deposits. In addition, 10 6 M selective 2 agonist UK14304 induced a significantly stronger antilipolytic effect in s.c. than in perigonadal fat cells (75·7 7·4% inhibition vs 52·5 4·1%) with similar efficacy (EC 50 =112 25 nM in perigonadal and 68 26 nM in s.c. fat cells), confirming the higher responsiveness to 2-adrenergic stimulation in s.c. adipocytes from transgenic mice (Fig. 4D) .
Effects of an HFD; physiological consequences in transgenic mice
Since 2A-AR expression has been described to increase with obesity (Lafontan & Berlan 1995) , control and transgenic mice were fed either an LFD or an HFD from age 3 to 21 weeks. The consequences of these diets were measured on body weight, adipocyte size, adipocyte gene expression of lipid metabolism, 2-adrenergic responsiveness, plasma parameters and blood pressure.
Body weight
No difference was observed between control and transgenic mice fed an LFD (Fig. 5A) . However, when fed an HFD, the body weight gain of transgenic mice was significantly elevated in comparison with control mice (Fig. 5B) . This difference became significant after 3 weeks of HFD (6-week-old animals) for the females and after 4 weeks of HFD (7-week-old animals) for the males. At the end of the diet period, the final weight gain of transgenic mice exceeded that of controls by 22% in males and 21% in females. This increased body weight was related to a rise of fat pad weight; the mass of perigonadal and s.c. fat deposits was higher in transgenic compared with control mice fed an HFD (Table 2 ). These results indicate that 2A-AR expression in WAT enhances the fattening effect of HFD.
Adipocyte size
To assess the contribution of fat cell size and/or adipocyte number in the expansion of adipose tissue, fat cell size and DNA content were measured. This was done in adipose tissue from female transgenic mice since they had a higher fat pad weight gain than males. In addition, the measurements were made in female perigonadal adipose tissue in which the largest increase of mass was observed. The diameter of perigonadal adipocytes from female transgenic mice fed an HFD was not significantly different from that of control mice fed an HFD or transgenic mice fed an LFD (Fig. 6) . The DNA content of perigonadal adipose tissue was twice as high in adipose tissue of transgenic females fed an HFD as in control (220·0 32·8 µg/fat pad, n=5, vs 111·6 15·0 µg/ fat pad, n=4, respectively, P<0·05). So, the development of WAT in 21-week-old transgenic mice fed an HFD is not associated with hypertrophy but rather with hyperplasia.
Adipocyte gene expression mRNA levels were determined in isolated perigonadal adipocytes and the expression of various genes involved in lipid metabolism was evaluated.
Values were normalized to ribosomal RNA levels. mRNA levels of genes involved in lipid storage and mobilization such as lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL), respectively, were studied. LPL mRNA levels were not modified whereas HSL mRNA levels were significantly lower in perigonadal adipocytes from HFD-fed transgenic compared with control mice (Table 3) . Recently, the cholesterol balance within Figure 5 Time course of body weight increase in male and female mice fed either a low-fat (LFD) or a high-fat (HFD) diet. After weaning, control (•) and transgenic () mice were subjected to either an LFD (A) or an HFD (B) for 18 weeks. Results are means±S.E.M. of 9-13 mice. *P<0·05 vs control, unpaired t-test. Table 2 Fat pad weight of control (m 3−/−, h 3+/+) and transgenic (m 3−/−, h 3+/+, h 2A+/−) mice fed a high-fat (HFD) or low-fat (LFD) diet for 18 weeks. Mice fed an LFD or HFD were killed at the age of 21 weeks and perigonadal (PG) as well as subcutaneous (SC) fat pads were dissected out and weighed (g). Data are means±S.E.M. from 9-13 mice
the adipocytes has been shown to be altered as a result of fat cell hypertrophy (Le Lay et al. 2001) . So, we compared the expression of several genes involved in cholesterol metabolism in control and transgenic mice fed an HFD. The sterol regulatory element binding protein-2 (SREBP2) gene and its targets like the low-density lipoprotein receptor (LDLR) (that controls the rate limiting steps for cholesterol uptake), the scavenger receptor type B1 (SR-B1), the ATP binding cassette that controls cholesterol efflux from cells, and the cavleolin 2 genes were not differentially expressed in adipocytes of transgenic vs control mice fed an HFD. All together, these results on gene expression confirm the absence of marked fat cell hypertrophy and suggest a reduced ability to mobilize fat in WAT of transgenic mice fed an HFD.
α2-adrenergic responsiveness
After an 18 week period of HFD associated with a rise in fat pad mass and body weight, the maximal antilipolytic effect of 10 6 M UK14304 in adipocytes of transgenic mice (52·3 7·5% inhibition vs 78·2 2·4%, n=3 in perigonadal and s.c. fat cells respectively) was not modified. The maximum number of 2A-AR sites was unchanged also (Table 4) .
Serum parameters and glucose tolerance tests
Obesity is often associated with glucose intolerance and the development of type II diabetes. In order to know whether the obese transgenic mice had any metabolic disturbances, blood glucose, serum insulin and NEFA levels were measured. No significant differences were observed in glucose or insulin levels between transgenic and control mice (male and female) at the end of the HFD period ( Table 5 ). Glucose tolerance tests (Fig. 7) revealed an apparent but not significant rightward shift of the curve following i.p. glucose injection associated with a slight alteration in insulin sensitivity (not shown) between control and transgenic mice fed an HFD. NEFA in serum were only significantly different between female control and transgenic mice fed an HFD (Table 5) .
Mean blood pressure
Hypertension, another disease commonly associated with obesity, was also evaluated. Mean blood pressure was compared between control and transgenic mice fed an HFD or an LFD. No significant difference was observed ( Table 6 ), indicating that this model of obese transgenic mice does not develop hypertension. 
Figure 7
Glucose tolerance tests in control and transgenic mice fed an HFD. Glucose was determined on blood samples from the tail vein of control () and transgenic mice () fed an HFD for 18 weeks. Data are means±S.E.M. for n=6 mice in each group. 
Discussion
In this study, genetic engineering was used in the mouse to promote the expression of human 2A-ARs under the control of human 2A-AR gene regulatory elements. The human transgene was expressed in mouse WAT and the physiological significance of the 2A-AR was investigated. The 2/ -AR functional balance mimics that previously described in human WAT. Interestingly, like in humans, a regulation of 2A-AR expression, according to the fat pad location, was also found. Stimulation of 2A-AR induced resistance to catecholamine-induced lipolysis mainly in s.c. adipose tissue. Only transgenic mice fed an HFD become obese without modification of fat cell size. Analysis of adipocyte gene expression related to lipid metabolism in transgenic mice fed an HFD suggested reduced lipid mobilization and no changes in lipid storage capacity.
The distribution of 2-ARs is known to be widespread in both humans and animals. Tissue specificities have been described concerning the distribution of different 2-AR mRNA subtypes: 2C2, 2C4 and 2C10 genes encoding 2B-, 2C-and 2A-AR respectively (Handy et al. 1993 , Berkowitz et al. 1994 . Although most of the tissues usually express more than one 2-AR subtype, white adipocytes only express the 2A-AR subtype in humans (Castan et al. 1995) . This receptor is not expressed in mouse adipocytes but is weakly expressed in rats adipocytes . Moreover, in rodents, 2A-AR, formerly called 2D-AR, exhibits pharmacological differences when compared with human 2A-AR (Cheung et al. 1982) . Thus, we transgenically expressed the human 2C10 gene encoding the 2A subtype in mice under its regulatory elements. Surprisingly, in tissues already known to express 2A-AR such as brain, transgenic mice did not overexpress human 2A-ARs mRNA or protein (identified by binding studies). By contrast, overexpression of 2A-AR mRNA and protein was observed in transgenic mouse white adipocytes leading to a functional antilipolytic response with an 2 agonist. According to these results, we hypothesize that the human DNA fragment used (e.g. 5 -, 3 -flanking and coding sequences of the human 2C10 gene) and the endogenous promoter of the murine 2C10 could compete differently for murine brain or WAT-specific transcription factors leading to differences in human receptor expression in these tissues. Indeed, human 2A-AR was not detected in brain while it was expressed in adipocytes of transgenic mice. Moreover, human and rodent 2A-ARs can be pharmacologically distinguished by the use of the 2 antagonist yohimbine (Link et al. 1992) ; rodent 2A-AR exhibits a lower affinity for this compound than human 2A-AR. In wild type and transgenic mice brains, competition studies performed with yohimbine revealed the predominance of the murine over the human 2A-AR. Nevertheless, we cannot totally exclude the presence of some human 2A-AR undetected by the binding assay. Analysis of 2A-AR mRNA revealed the absence or a very weak signal in BAT (probably due to some white adipocyte contamination), but no receptor protein was detected. In kidney, high K d values for [ 3 H]RX821002 (typical of other 2-AR subtypes such as 2C and 2B) stress the fact that the human 2A-AR is poorly expressed in this tissue by comparison with other subtypes. No signal was found in tissues known not to express 2A-AR such as liver.
The transgenic mice used in the present study express both the 2A-and 3-AR human transgenes and are lacking murine 3-AR. No significant modification of body weight or fat mass has been observed in mice overexpressing human 3-AR in BAT (m 3 / , h 3+/+ mice). 3-AR defects are usually associated with the development of obesity (Collins et al. 1994) . In mice lacking murine 3-AR, no significant increase of body weight has been found while the total body fat stores were significantly higher (Susulic et al. 1995 , Revelli et al. 1997 . So, it is not excluded that disruption of the 3-AR gene leads to a predisposition to the development of obesity or to compensatory adaptations of endogenous 1/ 2-AR that will limit the development of obesity. Slight variations of 1-AR and 2-AR mRNA levels have been reported in 3-AR null mice vs wild type mice (Susulic et al. 1995) . In the present study, no modification was observed in the amount of 1/ 2-AR protein of WAT from transgenic mice. These amounts were similar to values reported by Commins et al. (2000) in 3-ARdeficient mice. 2A-AR expression in WAT of transgenic mice did not change 1/ 2-AR number either. However, the presence of human 2A-AR and the absence of murine 3-AR in adipose tissue combined with HFD feeding caused a 20% increase in body weight. These results agree with those
